{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:32:39Z","timestamp":1761708759421,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,1,10]],"date-time":"2005-01-10T00:00:00Z","timestamp":1105315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anaesthesia"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Drotrecogin alfa (activated) is licensed in Europe for the treatment of severe sepsis in patients with multiple organ failure. We constructed a model to assess the cost effectiveness of drotrecogin alfa (activated) from the perspective of the UK National Health Service when used in adult intensive care units. Patient outcomes from a 28\u2010day international clinical trial (PROWESS) and a subsequent follow\u2010up study (EVBI) were supplemented with UK data. Cost effectiveness was assessed as incremental cost per life year and per quality adjusted life year saved compared to placebo alongside best usual care. Applying the 28\u2010day mortality outcomes of the PROWESS study, the model produced a cost per life year saved of \u00a34608 and cost per quality adjusted life year saved of \u00a36679. Equivalent results using actual hospital outcomes were \u00a37625 per life year and \u00a311\u2003051 per quality adjusted life year. Drotrecogin alfa (activated) appears cost effective in treating severe sepsis in UK intensive care units.<\/jats:p>","DOI":"10.1111\/j.1365-2044.2004.04068.x","type":"journal-article","created":{"date-parts":[[2005,1,10]],"date-time":"2005-01-10T04:11:28Z","timestamp":1105330288000},"page":"155-162","source":"Crossref","is-referenced-by-count":39,"title":["Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom*"],"prefix":"10.1111","volume":"60","author":[{"given":"A.","family":"Davies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,10]]},"reference":[{"key":"e_1_2_16_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200107000-00002"},{"key":"e_1_2_16_3_2","first-page":"S284","article-title":"Severe sepsis \u2013 A European estimate of the burden of disease in ICU","volume":"27","author":"Davies A","year":"2001","journal-title":"Intensive Care Medicine"},{"key":"e_1_2_16_4_2","first-page":"S252","article-title":"The prevalence of severe sepsis in the first 24 hours in the ICU, in England, Wales and Northern Ireland","volume":"27","author":"Padkin AJ","year":"2001","journal-title":"Intensive Care Medicine"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199909000-00010"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441001"},{"key":"e_1_2_16_7_2","first-page":"S51","article-title":"The effects of drotrecogin alfa (activated) on long\u2010term survival after sepsis","volume":"122","author":"Angus D","year":"2002","journal-title":"Chest"},{"key":"e_1_2_16_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200301000-00001"},{"key":"e_1_2_16_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa020969"},{"key":"e_1_2_16_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2003.10.005"},{"volume-title":"Methods for the Economic Evaluation of Health Care Programmes","year":"1997","author":"Drummond MF","key":"e_1_2_16_11_2"},{"volume-title":"Guidance for Manufacturers and Sponsors. (Technology Appraisals Process Series No. 5)","year":"2001","author":"National Institute for Clinical Excellence","key":"e_1_2_16_12_2"},{"key":"e_1_2_16_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9"},{"key":"e_1_2_16_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.903"},{"key":"e_1_2_16_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2003.03205.x"},{"key":"e_1_2_16_16_2","unstructured":"Government Actuary's Department.[WWW document].http:\/\/www.gad.gov.uk\/Life_Tables\/Interim_life_tables.htm[accessed on 22 September 2002]."},{"key":"e_1_2_16_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2001.40202-165.x"},{"key":"e_1_2_16_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050388"},{"key":"e_1_2_16_19_2","unstructured":"NettenA CurtisL.NHS 1988\/89\u20132001\/2002 inflation indices.Personal and Social Services Research Unit. Unit Costs of Health & Social Care.2002;187.http:\/\/www.pssru.ac.uk\/pdf\/uc2002\/Unit%20Costs%202002.pdf[accessed on 17 September 2004]."},{"volume-title":"The Health Service, Financial Database & Comparative Tool.","year":"2003","author":"Institute of Public Finance.","key":"e_1_2_16_20_2"},{"volume-title":"British National Formulary","year":"2002","author":"Anonymous.","key":"e_1_2_16_21_2"},{"volume-title":"What Is NICE's Threshold? an External View","year":"2002","author":"Towse A","key":"e_1_2_16_22_2"},{"key":"e_1_2_16_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2003.03568.x"},{"key":"e_1_2_16_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.864"},{"key":"e_1_2_16_25_2","unstructured":"National Institute for Clinical Excellence.Drotrecogin alfa (activated) for severe sepsis.Technology Appraisal 84.2004.http:\/\/www.nice.org.uk\/pdf\/TA084guidance.pdf[accessed 22 September 2004]."}],"container-title":["Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2044.2004.04068.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/associationofanaesthetists-publications.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2044.2004.04068.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T22:26:25Z","timestamp":1761690385000},"score":1,"resource":{"primary":{"URL":"https:\/\/associationofanaesthetists-publications.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2044.2004.04068.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,10]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1111\/j.1365-2044.2004.04068.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2044.2004.04068.x","archive":["Portico"],"relation":{},"ISSN":["0003-2409","1365-2044"],"issn-type":[{"type":"print","value":"0003-2409"},{"type":"electronic","value":"1365-2044"}],"subject":[],"published":{"date-parts":[[2005,1,10]]}}}